Kenrick Ng, Consultant Medical Oncologist at Barts Experimental Cancer Medicine Centre, shared on X:
“My prostate cancer picks for ESMO26 – a thread
Presidential session: DASL-HiCaP (LBA4, Sun 25 Oct, 16:30): intensified AR-targeted therapy with RT in very high-risk localised and post-prostatectomy disease.
Fri 23 Oct, 13:30 / Rapid oral
2219RO and 2220RO: ctDNA in mPCa: In many healthcare settings, ctDNA could soon guide early response assessment and molecular profiling without re-biopsy.
Pair with 2339eP: SR and meta-analysis of ctDNA in mPCa.
Fri 23 Oct, 15:15 / Posters
- 2272P: PSA nadir >0.2 ng/mL as a biologically aggressive subgroup. A simple, cheap signal that patients understand.
- 2382eTIP: Phase II trial testing whether men with mHSPC and suboptimal PSA response should receive intensification
Fri 23 Oct, 16:15 / Symposium:
emerging strategies in advanced PCa AR-directed advances, immune approaches, radioligands and new targets.
See you in Madrid!”
This can be interesting:
